Search results for: type 1 diabetes

Rheuminations: Epigenetics May Help to Explain Why Some Get Rheumatic Disease

Simon M. Helfgott, MD | March 1, 2013

Recent research around genes and environmental stresses suggests outside influences can make lasting changes to the genome via epigenetic mechanisms

A Spotlight on IgG4-Related Disease

Emine Atac, MD, and John H. Stone, MD, MPH | January 1, 2013

What rheumatologists need to know about identifying and diagnosing immunoglobulin G4-related disease (IgG4-RD)

As Population Ages, Rheumatologists Prepare to Treat Elderly Patients with More Comorbidities

Vanessa Caceres | November 1, 2012

Cardiovascular disease, diabetes are among the conditions that add another layer of complexity in treating older rheumatology patients

Rheumatology Drug Updates: Apremilast, Golimumab, and More

Michele B. Kaufman, PharmD, BCGP | November 1, 2012

Information on new approvals and medication safety rheumatologists need to know

Treat to Target: Rheumatoid Arthritis in Pregnant Patients

Eliza F. Chakravarty, MD, MS | October 1, 2012

A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

Drug Updates: Lorcaserin, Acetaminophen, and More

Michele B. Kaufman, PharmD, BCGP | September 5, 2012

information on new approvals and medication safety

Rheumatology Students Learning How To Look for Symptoms

Simon M. Helfgott, MD | August 8, 2012

First impressions and presumptions can lead us astray if we don’t pay attention.

Gene Mutation Could Cause Gut Microbe Changes that Lead to RA

David Holzman | July 31, 2012

A new study suggests that a small abnormality in an immunity gene can alter the gut flora in a way that induces development of rheumatoid arthritis.

Orthotics Part of Arthritis Treatment

Kurt Ullman | June 10, 2012

Although no cure, assistive devices can have an impact on pain of arthritis in the lower extremities

The Mystery of IVIg

Eveline Wu, MD, Michael M. Frank, MD | March 8, 2012

Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.